NCT01833572View on ClinicalTrials.gov

Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Non-small-cell Lung Cancer
Interventions
DRUG

Gefitinib

Eligible participants will be given orally gefitinib 250mg daily before surgery for 42 days or until disease progression or unacceptable toxicity. Best supportive care is allowed in this period.

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT01833572 - Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001) | Biotech Hunter | Biotech Hunter